John Bertoni, MD, PhD

Dr. BertoniProfessor - Department of Neurological Sciences
Director - Parkinson’s Disease Program

Academic Office:  Clinic Practice Location: 
988440 Nebraska Medical Center
Omaha, NE 68198-8440
Phone: 402-559-5569
Fax: 402-559-3341
4242 Farnam Street, Suite 650
North Doctor's Tower
Omaha, NE 68131
Phone: 402-559-8600  

Administrative Assistant:  Tova Safford     402-559-5569

Education:
University of Michigan, M.D. (1971)
Neurology, University of Michigan, Resident (1975)
Neurochemistry, University of Michigan, Fellowship (1978)
University of Michigan, Ph.D. (1979)

Hospital Appointments:
University of Nebraska Medical Center
VA Nebraska-Western Iowa Health Care System

Interests: Parkinson’s Disease

Biographical Sketch:
Dr. Bertoni is a Professor in the Department of Neurological Sciences at the University of Nebraska Medical Center and Director of the Parkinson’s Disease Clinic. Dr. Bertoni received his M.D. and Ph.D. (Neuroscience) from the University of Michigan in Ann Arbor. He also attended the University of Michigan in Ann Arbor to complete his residency in neurology and his fellowship in neurochemistry. Prior to joining the UNMC faculty in December 2008, Dr. Bertoni spent 19 years at Creighton University Medical Center as Chairman of the Department of Neurology. Prior to coming to Nebraska, Dr. Bertoni held academic appointments in Michigan, Texas, Pennsylvania and Delaware. Currently Dr. Bertoni is seeing patients with Parkinson’s disease and participating in several Parkinson’s Disease related studies.

Selected Publication:

  1. Bertoni JM, Sprenkle P, Strickland D, Noedel N: Evaluation of Parkinson's disease in entrants on the Nebraska State Parkinson's Disease Registry. Movement Disorders 21 (10):1623-6, 2006.
  2. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson’s Study Group [member of Study Group], Tempo and Presto Investigators: Safety of Rasagiline in Elderly Patients with Parkinson’s Disease. Neurology 66:1427-1429, 2006.
  3. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter C, Rudolph A, Shults C, Wojcieszek J, Foroud T and the Parkinson Study Group-PROGENI Investigators: R1514Q Substitution in LRRK2 is not a Pathogenic Parkinson’s Disease Mutation. Movement Disorders 22(2):254-257, 2007.
  4. Pankrantz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC, and the Parkinson Study Group-PROGENI Investigators: Presence of an APOE4 Allele Results in Significantly Earlier Onset of Parkinson’s Disease and a Higher Risk With Dementia. Movement Disorders 21(1): 45-49, 2006.
  5. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators: Mutations in LRRK2 Other than G2019S are Rare in a North American-Based Sample of Familial Parkinson Disease. Movement Disorders 21(12): 2257-2260, 2006.
  6. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators: Mutations in DJ-1 are Rare in Familial Parkinson Disease. Neuroscience Letters 408:209-213, 2006.
  7. Bertoni JM, Arlette JP, Fernandez HH, Frei K, Gordon MF, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr.: Parkinson’s Disease and Melanoma: An Epidemiologic Evaluation. The Movement Disorder Society’s 10th International Congress of Parkinson’s Disease and Movement Disorders, Kyoto, Japan, October 28-November 2, 2006.
  8. Lew M, Pahwa R, Leehey M, Bertoni J, Kricorian G and the Zydis Selegiline Study Group: Safety and Efficacy of Newly Formulated Selegiline Orally Disintegrating Tablets as an Adjunct to Levodopa in the Management of “Off” Episodes in Patients with Parkinson’s Disease. Current Medical Research and Opinion: Vol. 23, No. 4, 741-750, 2007. 
  9. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A and the Parkinson Study Group-PRECEPT Investigators: Serum Urate Predicts Progression of Parkinson’s Disease. Arch Neurol 65:716-723, 2008.
  10. Elmer LW, Bertoni JM, The Increasing Role of Monoamine Oxidase Type B inhibitors in Parkinson’s Disease Therapy. Expert Opin Pharmacother 9:2759-2762, 2008.
  11. Pankrantz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T for the Parkinson’s Study Group-PROGENI Investigators: Clinical Correlates of Depressive Symptoms in Familial Parkinson’s Disease. Movement Disorders 23(15):2216-2223, 2008. 
  12. Nichols WC, Kissell DK, Pankrantz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T and For the Parkinson Study Group PROGENI Investigators: Variation in GIGYF2 Is Not Associated With Parkinson Disease. Neurology 72:1886-1892, 2009. 
  13. Antony A, Bertoni JM. E-Pearl of the Week-Mirror Movements. Neurology September 23, 2009.
  14. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE Jr. Increased Melanoma Risk in Parkinson Disease: A Prospective Clinicopathological Study. Arch Neurol.2010:67(3):347-352. 
  15. Bertoni JM, Stoessl AJ, Elmer L, Borgohain R, Mori A, Kilborn J, Sussman NM and the 6002-INT-001 Study Group. Long Term Safety of Istradefylline in Parkinson’s Disease Subjects with Motor Fluctuations. Submitted to Arch Neurol. 2010.

;